Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8067-8067
◽
2010 ◽
Vol 103
(3)
◽
pp. 347-353
◽
2017 ◽
Vol 12
(5)
◽
pp. e46-e47
◽
2012 ◽
Vol 18
(3 Supplement)
◽
pp. B34-B34
2012 ◽
2011 ◽
Vol 17
(24)
◽
pp. 7796-7807
◽